ANS Pharmacology: Cholinergic Transmission and Receptor Types

Introduction/Overview

Cholinergic transmission constitutes a fundamental component of autonomic nervous system (ANS) signaling, mediating a wide array of physiological processes ranging from cardiovascular regulation to gastrointestinal motility. The neurotransmitter acetylcholine (ACh) exerts its effects through two principal classes of receptors: nicotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine receptors (mAChRs). The intricate interplay between these receptor subtypes underlies both normal autonomic function and the therapeutic modulation of autonomic disorders. A comprehensive understanding of cholinergic pharmacology is therefore indispensable for clinicians and pharmacists engaged in the management of conditions such as myasthenia gravis, glaucoma, urinary incontinence, and postoperative ileus.

Learning objectives for this chapter include:

• Describe the structural and functional diversity of nicotinic and muscarinic acetylcholine receptors.
• Explain the pharmacodynamic mechanisms by which cholinergic agents modulate autonomic pathways.
• Summarize the pharmacokinetic profiles of representative cholinergic drugs.
• Identify therapeutic indications and off‑label uses of cholinergic agents.
• Recognize common adverse effects, drug interactions, and special population considerations associated with cholinergic pharmacotherapy.

Classification

Drug Classes and Categories

Cholinergic agents are broadly categorized into agonists, antagonists, and inhibitors of acetylcholinesterase (AChE). Within each category, drugs are further subdivided based on receptor selectivity and site of action.

• Agonists
  • Non‑selective nicotinic agonists (e.g., nicotine, varenicline)
  • Selective nicotinic agonists (e.g., epibatidine derivatives)
  • Non‑selective muscarinic agonists (e.g., pilocarpine, carbachol)
  • Selective muscarinic agonists (e.g., methacholine, oxotremorine)
• Antagonists
  • Non‑selective nicotinic antagonists (e.g., curare, d-tubocurarine)
  • Selective nicotinic antagonists (e.g., mecamylamine, hexamethonium)
  • Non‑selective muscarinic antagonists (e.g., atropine, scopolamine)
  • Selective muscarinic antagonists (e.g., pirenzepine, ipratropium)
• AChE Inhibitors
  • Non‑selective inhibitors (e.g., physostigmine, neostigmine)
  • Selective inhibitors (e.g., pyridostigmine, edrophonium)

Chemical Classification

Cholinergic drugs can be grouped according to their core chemical scaffolds:

• Alkaloids (e.g., nicotine, scopolamine)
• Quaternary ammonium compounds (e.g., succinylcholine, atracurium)
• Organophosphates (e.g., sarin, chlorpyrifos)
• Carbamates (e.g., physostigmine, pyridostigmine)
• Non‑phosphorus, non‑carbamate AChE inhibitors (e.g., edrophonium)

Mechanism of Action

Pharmacodynamics

Acetylcholine is synthesized in cholinergic neurons by choline acetyltransferase and released into the synaptic cleft upon depolarization. It binds to nAChRs, which are ligand‑gated ion channels, or to mAChRs, which are G‑protein coupled receptors (GPCRs). The downstream effects of receptor activation differ markedly between the two classes.

Nicotinic Acetylcholine Receptors

nAChRs are pentameric complexes composed of various combinations of α, β, γ, δ, and ε subunits. The most common neuronal subtype is α4β2, whereas the muscle‑type receptor is α1β1γδ (or α1β1δε in adult muscle). Binding of ACh to the extracellular domain induces a conformational change that opens the central pore, allowing Na⁺ influx and K⁺ efflux, thereby depolarizing the postsynaptic membrane. This depolarization triggers action potentials in autonomic ganglia and skeletal muscle fibers. Agonists such as nicotine mimic ACh, whereas antagonists block ion flow, leading to neuromuscular blockade.

Muscarinic Acetylcholine Receptors

mAChRs are subdivided into five subtypes (M1–M5). Each subtype couples to distinct G‑protein pathways:

• M1, M3, M5: Gq/11 → phospholipase C → IP₃/DAG → Ca²⁺ release and protein kinase C activation.
• M2, M4: Gi/o → inhibition of adenylate cyclase → ↓cAMP → reduced PKA activity.

Activation of M1 receptors in the central nervous system enhances cognitive function, whereas M2 receptors in the heart decrease heart rate and contractility. M3 receptors mediate smooth muscle contraction and glandular secretion. The selective activation or blockade of these subtypes underlies the therapeutic effects of muscarinic agents.

Molecular/Cellular Mechanisms of Cholinergic Modulators

Agonists bind to the orthosteric site, stabilizing the active conformation of the receptor. Antagonists occupy the same site without inducing conformational changes, thereby preventing endogenous ligand binding. Partial agonists produce submaximal responses even at full occupancy. In the case of AChE inhibitors, the enzyme’s active site is covalently modified, prolonging ACh availability in the synaptic cleft. The degree of inhibition depends on the inhibitor’s affinity, reversibility, and ability to cross the blood‑brain barrier.

Pharmacokinetics

Absorption

Oral absorption of cholinergic drugs varies widely. Quaternary ammonium compounds exhibit poor gastrointestinal permeability due to their permanent positive charge, necessitating parenteral administration. In contrast, lipophilic carbamate inhibitors (e.g., physostigmine) cross the intestinal mucosa efficiently. Intranasal and transdermal routes are employed for agents such as scopolamine and pilocarpine, respectively, to achieve rapid onset and bypass first‑pass metabolism.

Distribution

Distribution is influenced by lipophilicity, plasma protein binding, and the presence of active transporters. Lipophilic agents penetrate the central nervous system (CNS) readily, whereas hydrophilic quaternary ammonium compounds are largely confined to the peripheral compartment. The volume of distribution (Vd) for succinylcholine is approximately 0.2 L/kg, reflecting its limited tissue uptake. In contrast, pyridostigmine demonstrates a Vd of 0.5 L/kg, indicating moderate distribution into tissues.

Metabolism

Metabolic pathways differ among drug classes. Carbamate AChE inhibitors undergo hydrolysis by esterases, yielding inactive metabolites. Organophosphates are metabolized by cytochrome P450 enzymes, producing oxon derivatives that exhibit higher AChE affinity. Nicotinic antagonists such as d-tubocurarine are metabolized via hepatic oxidation and conjugation. The presence of hepatic impairment can prolong drug action, particularly for agents with extensive first‑pass metabolism.

Excretion

Renal excretion predominates for hydrophilic cholinergic agents. Neostigmine is eliminated unchanged via glomerular filtration, with a half‑life of 1–2 h in healthy adults. In patients with renal dysfunction, dosing intervals must be extended to avoid accumulation. Hepatic excretion is significant for lipophilic compounds; for example, physostigmine is metabolized in the liver and excreted in bile.

Half‑Life and Dosing Considerations

Half‑life ranges from minutes (succinylcholine, 1–2 min) to hours (neostigmine, 1–2 h). Dosing regimens are tailored to the drug’s pharmacokinetic profile and therapeutic target. For neuromuscular blockade, a loading dose followed by continuous infusion may be required. In contrast, cholinergic agonists for glaucoma are administered as eye drops, with a dosing interval of 2–4 h to maintain intraocular pressure control.

Therapeutic Uses/Clinical Applications

Approved Indications

• Neuromuscular Blockade – Succinylcholine, atracurium, rocuronium, and vecuronium are employed during general anesthesia to facilitate tracheal intubation and surgical relaxation.
• Myasthenia Gravis – Pyridostigmine and neostigmine improve muscle strength by inhibiting AChE at the neuromuscular junction.
• Glaucoma – Pilocarpine and carbachol lower intraocular pressure by stimulating ciliary muscle contraction and aqueous humor outflow.
• Urinary Incontinence – Tolterodine, solifenacin, and darifenacin selectively block M3 receptors in the bladder detrusor muscle.
• Postoperative Ileus – Neostigmine can accelerate gastrointestinal motility in selected patients.
• Organophosphate Poisoning – Physostigmine and atropine are used in emergency management to counteract cholinergic crisis.

Off‑Label Uses

Cholinergic agents are occasionally employed beyond their approved indications. For instance, atropine is used to reduce salivation during dental procedures, and scopolamine is prescribed for motion sickness. Nicotinic agonists such as varenicline are utilized for smoking cessation, exploiting their partial agonist activity at α4β2 receptors. Additionally, muscarinic antagonists are investigated for their potential in treating neurodegenerative disorders, such as Alzheimer’s disease, by modulating central cholinergic deficits.

Adverse Effects

Common Side Effects

• Gastrointestinal: nausea, vomiting, abdominal cramps, diarrhea (predominant with cholinergic agonists).
• Cardiovascular: bradycardia, hypotension, arrhythmias (especially with atropine and scopolamine).
• Neurological: dizziness, headache, blurred vision, mydriasis (common with anticholinergics).
• Respiratory: bronchoconstriction (notably with muscarinic agonists in asthmatic patients).

Serious/Rare Adverse Reactions

Severe cholinergic crisis, characterized by muscle fasciculations, respiratory failure, and hyperthermia, may occur with organophosphate exposure or overdose of AChE inhibitors. Anticholinergic toxicity can lead to delirium, seizures, and hyperthermia. Rarely, hypersensitivity reactions such as anaphylaxis have been reported with succinylcholine and other neuromuscular blockers.

Black Box Warnings

Physostigmine carries a black box warning for the potential to precipitate seizures and arrhythmias, particularly in patients with pre‑existing cardiac conduction abnormalities. Atropine is cautioned against in patients with narrow‑angle glaucoma due to the risk of angle closure.

Drug Interactions

Major Drug‑Drug Interactions

• Anticholinergic agents (e.g., antihistamines, tricyclic antidepressants) potentiate the effects of cholinergic antagonists, increasing the risk of anticholinergic toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may reduce the efficacy of AChE inhibitors by inhibiting prostaglandin‑mediated pathways involved in cholinergic signaling.
• Beta‑blockers can mask bradycardic responses to cholinergic agonists, complicating cardiac monitoring.
• Organophosphate pesticides interact synergistically with AChE inhibitors, exacerbating cholinergic toxicity.

Contraindications

Contraindications include hypersensitivity to the drug, severe hepatic or renal impairment (for agents predominantly cleared by these organs), and concurrent

References

1. Barrett KE, Barman SM, Brooks HL, Yuan JX. Ganong's Review of Medical Physiology. 26th ed. New York: McGraw-Hill Education; 2019.
2. Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th ed. Philadelphia: Elsevier; 2021.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.